What is AORT's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for AORT.

Stock Ratings / Health Care / AORT / options

PRCT (38) ATEC (34) BVS (61) SGP (43) ⌘ Pro Terminal →

Artivion Inc. (AORT) Options Positioning, Max Pain & Unusual Sweeps

$23.58 +4.43% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $23.72

Artivion Inc. (AORT) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.10B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AORT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AORT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Artivion Inc. (NYSE: AORT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $23.58 (+4.43% 1D, market cap $1.10B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, AORT ranks #460 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AORT compare to PRCT and ATEC in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), AORT carries a Roarable D- (40/100 RQD), trailing P/E of 117.0x, gross margin of 64.4%, and ROIC of 4.5%. By comparison, PRCT (PROCEPT BioRobotics Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $1.10B) and ATEC (Alphatec Holdings Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -18.4%, cap $1.09B). Among the 5-stock peer group, BVS leads on earnings multiple (55.0x) while BVS leads on capital efficiency (10.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AORT?

▼

Per AORT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000784199), Artivion Inc. generated $441.3M in revenue (+13.6% YoY), $9.8M in net income, and $839.0K in free cash flow against $884.8M in total assets and $215.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $23.72 (+0.61%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AORT)Realized 20D OHLCV Swing Band: ±8.8%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY AORT SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (33% of score)

Altman Z-Score 2.46 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (23% of score)

FRED Regime × Technicals: 15% of 52W Range • RSI-14 at 47 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$21.36+8.1% Next Q

Q2 (-2Q)

Grade E$23.09-0.6% Next Q

Q3 (-1Q)

Grade E$22.94+2.8% Next Q

Current

Grade D-$23.58-7.4% Hist 90D α

Trajectory: E (32) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AORT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AORT currently carries a cautious 40/100 (D-) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.69) and Max Pain ($24.76) forces dealer call-delta covering toward $50.66.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+1.08% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AORT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AORT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±8.8%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (AORT)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for AORT.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AORT)

✓Walkthrough of AORT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AORT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.63%▲ ASCENDING CHANNEL

2026-11-03O $23.44H $23.58L $22.58C $23.58VOL 627.4K

RES: $38.28SUP: $20.38SMA50: $23.69SMA200: $29.19

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AORT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AORT Butterfly Map → + Track AORT →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

48.0%/yr Implied 5Y Growth

vs. +13.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AORT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AORT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AORT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AORT)

Health Care Rank #460 of 1016 ⚔️ PRCT vs AORT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AORT vs. PRCT, ATEC, BVS, SGP)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Artivion Inc. (AORT) ranks #460 by composite RQD confidence (40/100, grade D-) and #344 by equity capitalization ($1.10B). Within this direct 5-issuer industry benchmark cohort, BVS leads on earnings valuation at 55.0x trailing P/E, while BVS leads on capital efficiency and profitability with 10.4% ROIC and 68.3% gross margin. BVS currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with AORT at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AORT ACTIVE Artivion Inc.	D-	40/100	117.0x	64.4%	4.5%	+4.43%	$1.10B	Benchmark Subject
PRCT PROCEPT BioRobotics Corporation	D-	38/100	—	63.7%	-35.0%	+1.25%	$1.10B	/prct-vs-aort →
ATEC Alphatec Holdings Inc.	E	34/100	—	69.6%	-18.4%	+3.84%	$1.09B	/atec-vs-aort →
BVS Bioventus Inc. (Class A)	C-	61/100	55.0x	68.3%	10.4%	-1.31%	$1.12B	/bvs-vs-aort →
SGP SpyGlass Pharma Inc.	D-	43/100	—	—	-35.0%	+4.34%	$1.08B	/sgp-vs-aort →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000784199

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Artivion Inc. (AORT) reported GAAP revenue of $441.3M (+13.6% vs. FY2024 revenue of $388.5M , and +24.7% cumulative change since FY2023) , GAAP net income of $9.8M, operating cash flow of $39.9M, and free cash flow of $839.0K (-92.4% YoY). On the balance sheet, AORT closed FY2025 with $884.8M in total assets against $215.1M in total debt (Altman Z-Score: 2.46, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$441.3M	$9.8M	$39.9M	$839.0K	$884.8M	$215.1M
FY2024 (FY)	2024-12-31	$388.5M	-$13.4M	$22.2M	$11.0M	$789.1M	$314.2M
FY2023 (FY)	2023-12-31	$354.0M	-$30.7M	$18.8M	$18.8M	—	—

3. AORT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AORT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does AORT compare to PRCT and ATEC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for AORT?

Where is AORT trading relative to its 50-day, 200-day, and 52-week technical levels?

AORT last traded at $23.58 (+4.43% on volume of 626,190 shares), positioning the stock -0.46% below its 50-day simple moving average ($23.69) and -19.22% below its 200-day simple moving average ($29.19). Across its 52-week range of $19.16 to $48.25, AORT sits at the 15.2% percentile with a 14-day RSI of 47.0 (NEUTRAL RANGE) and an implied next-earnings move of ±8.8% ($21.50 to $25.66).

Direct Sub-Reports: AORT RQD Cockpit AORT 12M Forecast AORT Earnings & Move AORT Dividends & DRIP AORT Insiders & 13F AORT Whale Options AORT Profit Sankey AORT News & Why

ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ SEC XBRL & RQD VERIFIED

AORT — Artivion Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Artivion Inc. (AORT) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $23.58 (+4.43% 1D, market capitalization $1.10B).

Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of 4.5%, gross margin of 64.4%, operating margin of 7.6%, and free cash flow yield of 0.07%.
Whale 13F & Options Flow (5/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (9/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.46, Piotroski F-Score of 9/9, and Debt/Equity of 0.48x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Artivion Inc. (AORT) is a NYSE-listed issuer in the Health Care sector, Medical/Dental Instruments industry. — for product lines, customer base, or revenue model detail beyond the segment classification. Gross margin is 64.4%, operating margin 7.6%, and net margin 2.2%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Artivion Inc. (AORT) reported $441.3M in annual revenue (up from $388.5M in FY2024, +13.6% YoY) and $9.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($354.0M revenue, -$30.7M net income) through FY2025, AORT scaled operating cash flow to $39.9M and free cash flow to $839.0K, backed by $884.8M in total assets against $215.1M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 0.07% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $19.16 – $48.25 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 117.0x trailing P/E and 19.3x EV/EBITDA against 7.6% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), AORT carries a macro regime beta of 1.00 and gross margin of 64.4%.

Key Question #1: Can AORT sustain or expand its 7.6% operating margin and 4.5% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $441.3M and free cash flow of $839.0K, how will capital allocation balance growth reinvestment against $215.1M in total debt?
Key Question #3: How sensitive is AORT's 98.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

AORT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Artivion Inc. (AORT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AORT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance Singapore • 20h ago

Artivion, Inc. (AORT) stock price, news, quote and history

Yahoo Finance Singapore report covering Artivion Inc. (AORT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 23h ago

Artivion (AORT) Stock May Be 13% Undervalued On Cash Flow

Yahoo Finance report covering Artivion Inc. (AORT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Medical devices & supplies - cardiology, neurology, vascular stocks Q2 teardown: Artivion (NYSE:AORT) vs the rest

TradingView report covering Artivion Inc. (AORT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockStory • 1d ago

1 Small-Cap Stock with Exciting Potential and 2 We Turn Down

StockStory report covering Artivion Inc. (AORT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

How Investors May Respond To Artivion (AORT) Cautious Full Year Outlook

Simply Wall St report covering Artivion Inc. (AORT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

BlackRock updates its Artivion (AORT) stake; an iShares ETF has an interest above 5%.

Stock Titan report covering Artivion Inc. (AORT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Artivion, Inc. (AORT) Stock Forecasts

Yahoo Finance report covering Artivion Inc. (AORT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Artivion (AORT) Could Be 43% Undervalued On Strong Q2 Results And Mixed Guidance

Simply Wall St report covering Artivion Inc. (AORT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AORT Bull vs. Bear Conversation Board — What's Your Call at $23.58?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AORT 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $26.64 (+18.0%)

📌 Pinned Debate

The forensic balance sheet scores 13/20 with Altman Z 2.46, Piotroski F 9/9, and Debt/Equity 0.48, and debt fell from $314.2M to $215.1

Here is why I am bullish on AORT here at $22.58: The forensic balance sheet scores 13/20 with Altman Z 2.46, Piotroski F 9/9, and Debt/Equity 0.48, and debt fell from $314.2M to $215.1M while revenue grew to $441.3M.. Compare AORT's 7.6% operating margin and 4.5% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $21.45 are getting bought.

ArenaChamp_24 🐂 BULL

@ShortSeller_Dan Fair point on 117.0x trailing P/E, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (64.4%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $19.42 (-14.0%)

Spot @ $22.58

Free cash flow fell to $0.8M in FY 2025 and the FCF yield is 0.07% against a trailing P/E of 117, leaving the cash engine pillar at onl

Free cash flow fell to $0.8M in FY 2025 and the FCF yield is 0.07% against a trailing P/E of 117, leaving the cash engine pillar at only 5/20.. Look at the math on AORT: paying 117.0x trailing P/E for 4.5% ROIC and 7.6% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $19.87 before getting long.